View Older Stories View More Recent Stories

May 1, 2026 03:39PM BTIG Reiterates Buy Rating on Arvinas Inc. (ARVN)
May 1, 2026 01:12PM Arvinas shares gain as FDA approves breast cancer drug Veppanu
Mar 20, 2026 06:47AM H.C. Wainwright Reiterates Buy Rating on Arvinas Inc. (ARVN)
Mar 18, 2026 03:48PM Arvinas Inc. (ARVN) PT Raised to $16 at BTIG
Mar 18, 2026 11:18AM Truist Securities Reiterates Hold Rating on Arvinas Inc. (ARVN) amid positive Parkinson's data
Mar 6, 2026 06:46AM Piper Sandler on Arvinas Inc. (ARVN): 'Multiple Data Readouts to Drive Value in 2026'
Feb 24, 2026 02:24PM Arvinas Inc. (ARVN) PT Raised to $11 at Wedbush
Feb 24, 2026 07:08AM Arvinas, Inc. (ARVN) Misses Q4 EPS by 59c
Dec 21, 2025 04:00AM Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
Dec 8, 2025 02:55AM Arvinas presents preclinical data on ARV-393 drug combination
Nov 24, 2025 07:02AM Arvinas to present vepdegestrant data at breast cancer symposium
Nov 10, 2025 06:33AM Arvinas Inc. (ARVN) PT Raised to $15 at Stephens
Nov 5, 2025 07:18AM Arvinas, Inc. (ARVN) Tops Q3 EPS by 23c
Nov 3, 2025 04:00PM Arvinas to present ARV-393 data at ASH meeting in december
Oct 30, 2025 06:05AM Arvinas Inc. (ARVN) PT Raised to $14 at BTIG
Oct 24, 2025 04:00PM Arvinas presents preclinical data for cancer drug ARV-806
Oct 22, 2025 04:00PM Arvinas to present ARV-806 cancer drug data at October conference
Oct 15, 2025 02:42AM Goldman Sachs Downgrades Arvinas Inc. (ARVN) to Sell
Oct 7, 2025 08:27AM Arvinas Inc. (ARVN) PT Raised to $16 at Piper Sandler
Oct 6, 2025 09:08AM Arvinas Inc. (ARVN) PT Raised to $12 at BofA Securities
Sep 24, 2025 02:35AM BofA Securities Downgrades Arvinas Inc. (ARVN) to Neutral
Sep 19, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Arvinas Inc. (ARVN)
Sep 19, 2025 04:47AM Arvinas Inc. (ARVN) PT Lowered to $15 at Barclays
Sep 18, 2025 06:52AM Cantor Fitzgerald Reiterates Overweight Rating on Arvinas Inc. (ARVN)
Sep 18, 2025 06:49AM Arvinas Inc. (ARVN) PT Lowered to $9 at Wedbush
Sep 18, 2025 06:41AM Arvinas Inc. (ARVN) PT Lowered to $14 at Stephens
Sep 17, 2025 04:31PM Arvinas and Pfizer to out-license vepdegestrant commercialization rights
Sep 17, 2025 04:37AM Barclays Starts Arvinas Inc. (ARVN) at Overweight
Aug 8, 2025 04:05PM FDA accepts Arvinas drug application for advanced breast cancer treatment
Aug 7, 2025 06:53AM Arvinas Inc. (ARVN) PT Lowered to $15 at Guggenheim
Aug 6, 2025 07:50AM Arvinas, Inc. (ARVN) Tops Q2 EPS by 10c
Jul 9, 2025 07:00AM Arvinas CEO John Houston announces retirement plans
Jun 6, 2025 08:38AM Arvinas (ARVN) stock rises on FDA submission with Pfizer (PFE)
Jun 6, 2025 07:01AM Arvinas Inc. (ARVN) Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
Jun 3, 2025 07:05AM H.C. Wainwright Reiterates Buy Rating on Arvinas Inc. (ARVN)
Jun 2, 2025 01:10AM Leerink Partners Downgrades Arvinas Inc. (ARVN) to Market Perform
May 30, 2025 05:01AM Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
May 7, 2025 10:10AM Arvinas, Inc. (ARVN) Investors May Be Able to Recover Losses By Reaching Out To Block & Leviton Regarding Securities Fraud Investigation
May 5, 2025 06:58AM Arvinas Inc. (ARVN) PT Lowered to $24 at H.C. Wainwright
May 5, 2025 04:56AM Arvinas Inc. (ARVN) PT Lowered to $9.50 at Citi
May 5, 2025 01:04AM Truist Securities Downgrades Arvinas Inc. (ARVN) to Hold
May 2, 2025 05:35AM Arvinas Inc. (ARVN) PT Lowered to $16 at BTIG
May 2, 2025 05:30AM TD Cowen Downgrades Arvinas Inc. (ARVN) to Hold
May 1, 2025 04:30PM Jefferies Downgrades Arvinas Inc. (ARVN) to Hold
May 1, 2025 04:05PM Arvinas Inc. (ARVN) PT Lowered to $8 at Goldman Sachs
May 1, 2025 07:07AM Arvinas, Inc. (ARVN) Tops Q1 EPS by 214c
Apr 23, 2025 10:45AM Arvinas (ARVN) Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology
Apr 9, 2025 09:34AM Arvinas Inc. (ARVN) PT Lowered to $21 at Truist Securities
Apr 8, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Arvinas Inc. (ARVN)
Apr 4, 2025 07:01AM Arvinas Inc. (ARVN) Presents First-in-Human Data for Investigational Oral PROTAC ARV-102
View More Recent Stories View Older Stories